Anti–PD-1 Therapy Reverses HIV Latency in Patients with HIV and Cancer

Article navigation

Research Watch| April 01 2022

Online ISSN: 2159-8290

Print ISSN: 2159-8274

2022

American Association for Cancer Research.

Cancer Discov (2022) 12 (4): OF5.

Abstract

Anti–PD-1 monoclonal antibodies reversed HIV latency in CD4⁺ T cells after the first infusion.

2022

American Association for Cancer Research.

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.